Lecanemab

Medicine & Biotech · covered by 9 outlets this week · tracked since 2026-10-27

Press: 8 specialist 1 independent outlet-days

Background

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of mild Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. Wikipedia ↗

Written by the Alivewire editors from the coverage below, 19h ago. Not medical advice; how the ratings work.

Coverage

The view of clinicians on the NCPE decision

Medical Independent · 1d ago

Lecanemab’s five-year report card lands in Boston

Longevity.Technology · 2d ago

detranslation pending

Alzheimer-Antikörper: Erste Bilanz nach einem Jahr

Medinside · 2d ago

Eisai to unveil five-year Alzheimer’s drug data at CTAD 2026

Longevity.Technology · 12d ago

Blood proteins could indicate whether an Alzheimer's drug is workingProteine im Blut könnten Wirkung eines Alzheimer-Medikaments anzeigen

Deutsches Ärzteblatt · 14d ago

study

Alzheimer's Drug ARIA Monitoring: Real-World Study Results

MedPage Today Geriatrics · 27d ago

study

Blood clues to why Alzheimer’s drug results vary

Longevity.Technology · 27d ago

podcast

Receiving Alzheimer's Treatment: A Patient's Perspective

Speaking of Alzheimer's (Alzheimer's Association) · 608d ago

podcast

Delivering Alzheimer's Treatment: A Doctor's Perspective

Speaking of Alzheimer's (Alzheimer's Association) · 622d ago

Sources

Lecanemab

Background

Coverage